, which I can tell you has been a significant impact during this quarter. As we look ahead, we are committed to closely monitoring and managing our capital deployment internationally, and we will provide updates as we progress. Thank you.

Key Financial Metrics:

- Adjusted operating income of $34 million for DaVita Medical Group in the second quarter of 2017
- Adjusted EBITDA of $94 million for the quarter
- Guided 2017 adjusted operating income for DMG of $110 million to $150 million
- International operating losses of $13 million in the quarter
- Operating cash flow of $146 million in the second quarter
- Operating cash flow guidance for 2017 of $1.75 billion to $1.95 billion
- Repurchased nearly 3.6 million shares for $232 million in the second quarter

Overall, the report highlights the financial performance of DaVita Medical Group and its international operations, including operating income, EBITDA, cash flow, and capital deployment through stock repurchases. The company's guidance for adjusted operating income and cash flow for 2017 is also provided, giving insight into their future financial outlook. Additionally, challenges and opportunities in international markets, specifically in China, are discussed, indicating the company's strategic focus on global expansion.